The Department of Infectious Disease Immunology focuses on research and development of next-generation vaccines and diagnostic tools, primarily within tuberculosis (TB), chlamydia, and vaccine adjuvants. The Department conducts both basic and translational research and is highly rated internationally. As part of the SSI Center for Vaccine Research, we can efficiently move products from research into clinical trials. We collaborate closely with a large number of institutions and are externally funded by e.g. the National Institutes of Health, Bill and Melinda Gates Foundation, European Commission and the Danish Research Council. The Vaccine Adjuvant group aim at developing novel adjuvant formulations designed to induce the immunological profiles required for the specific diseases. You will be part of The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) as part of the group working on design of novel adjuvants for induction of mucosal immune responses
More information can be found: Center for Vaccine Research ( https://en.ssi.dk/research/center-for-vaccine-research/center-for-vaccine-research/vaccine-adjuvant-research )

QUALIFICATIONS

Key skills for formulating and testing novel adjuvants, involve a blend of expertise in pharmaceutical formulation and in vitro and in vivo immunological testing. We are searching for experts able to formulate and characterize immunostimulators in different cell cultures, including reporter cell lines and in vivo, with a focus to develop novel adjuvants eliciting airway immunity.

Key qualifications

• Dynamic, independent, creative and goal orientated with a strong immunological and pharmaceutical background
• Strong technical background in immunological methods including ELISA, Flow Cytometry and qPCR
• Knowledge and hands-on experience within in vitro and in vivo models of immunology

• Experience with adjuvant formulationCapable of handling a multifaceted project with many stakeholders and collaborators

• Establish nasal tissue primary cells and reporter lines
• Screen immunostimulators for immunostimulator activation
• Formulate and evaluate novel immunostimulators
• Study physicochemical properties of different delivery systems
• Investigate target cells and activation profile after intranasal delivery of novel adjuvant systemsStudy basic cellular and humoral local and systemic immune responses after intranasal administration of adjuvanted protein vaccine